Cochrane · systematic review · CD015167
Hyperimmune immunoglobulin for people with COVID‐19
Kimber, C, Valk, SJ, Chai, KL, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
11
No studies
2
Included studies
NR
No studies 2 · 14.3%Ungraded 1 · 7.1%Very low 1 · 7.1%Low 8 · 57.1%Moderate 2 · 14.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Hyperimmune immunoglobulin from human plasma compared to saline placebo
Population: individuals with moderate or severe COVID‐19
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality at day 28 Hyperimmune immunoglobulin from human plasma vs saline placebo | RR 0.79 [0.43, 1.44] | NR | Low Downgraded: imprecision |
Worsening of clinical status at day 28 (data only available for clinical status worsened on day 7) Hyperimmune immunoglobulin from human plasma vs saline placebo | RR 0.85 [0.58, 1.23] | NR | Very low Downgraded: imprecision, indirectness |
Improvement of clinical status (number of people discharged from hospital, or reaching category 1 on a 7‐point ordinal scale) Hyperimmune immunoglobulin from human plasma vs saline placebo | RR 1.02 [0.97, 1.08] | NR | Moderate Downgraded: imprecision |
Quality of life Hyperimmune immunoglobulin from human plasma vs saline placebo | no estimate extracted | NR | No studies |
Adverse events of any grade up to 28 days (data only available for adverse events up to day 1) Hyperimmune immunoglobulin from human plasma vs saline placebo | RR 0.98 [0.81, 1.18] | NR | Low Downgraded: imprecision, indirectness |
Adverse events at grades 3 to 4 up to 28 days Hyperimmune immunoglobulin from human plasma vs saline placebo | RR 4.09 [1.39, 12.01] | NR | Moderate Downgraded: imprecision |
Serious adverse events up to day 28 (data available only as a composite of serious adverse events or death up to day 28) Hyperimmune immunoglobulin from human plasma vs saline placebo | RR 0.72 [0.45, 1.14] | NR | Low Downgraded: imprecision |
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies (EpAbs) compared to saline placebo
Population: individuals with moderate or severe COVID‐19
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality (by day 28) RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies (EpAbs) vs saline placebo | RR 0.6 [0.26, 1.37] | 1 study · 241 participants | Low Downgraded: imprecision |
Worsening of clinical status (expressed as new need for IMV, admission to ICU, or death by day 28) RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies (EpAbs) vs saline placebo | RR 0.67 [0.38, 1.18] | 1 study · 241 participants | Low Downgraded: imprecision |
Improvement of clinical status (number of participants discharged from hospital by day 28) RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies (EpAbs) vs saline placebo | RR 1.06 [0.96, 1.17] | 1 study · 241 participants | Low Downgraded: imprecision |
Quality of life RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies (EpAbs) vs saline placebo | no estimate extracted | NR | No studies |
Adverse events of any grade (by day 28) RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies (EpAbs) vs saline placebo | RR 0.99 [0.74, 1.31] | 1 study · 243 participants | Low Downgraded: imprecision |
Adverse events at grade 3 or 4 (by day 28) RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies (EpAbs) vs saline placebo | OR 4 | 3 participants | Ungraded |
Serious adverse events (by day 28) RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies (EpAbs) vs saline placebo | RR 0.67 [0.38, 1.19] | 1 study · 243 participants | Low Downgraded: imprecision |